Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET

Company Participants

Hayleigh Collins - Director and Head of Corporate Communications

Sean Nolan - Chief Executive Officer

Sukumar Nagendran - President and Head of Research and Development

Kamran Alam - Chief Financial Officer

Conference Call Participants

Whitney Ijem - Canaccord Genuity

Jack Allen - Robert W. Baird & Co.

Silvan Tuerkcan - JMP Securities

Yun Zhong - BTIG

David Hoang - SMBC Nikko Securities

Joon Lee - Truist Securities

Operator

Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full-Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Hayleigh Collins, Director and Head of Corporate Communications. Thank you, Ms. Collins. You may begin.

Hayleigh Collins

Thank you. Good afternoon, and welcome to Taysha's fourth quarter and full-year 2022 financial results and corporate update conference call. I'm Hayleigh Collins, Taysha's recently appointed Director and Head of Corporate Communications. I will also be overseeing Investor Relations activities. Ever in corporate communications experience in rare diseases having previously served in a similar role at Jaguar Gene Therapy. I'm excited to join Taysha at this pivotal time and look forward to working with the team to help bring potentially life-changing therapies to patients with rare diseases with high unmet medical needs.

Earlier today, Taysha issued a press release announcing financial results for the fourth quarter and full-year 2022. A copy of this press release is available on the Company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's CEO, Sukumar Nagendran, President and Head of R&D and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward-looking statements, including statements relating to the existing clinical data for TSHA-120 and the therapeutic and commercial potential of TSHA-120 and TSHA-102. These statements may include expected timing and results of clinical trials of our product candidates and other clinical and regulatory plans and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not of historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements.